Skip to navigation Skip to content



About this Medication
  • Brand Name: Mayzent® (Māʹzĕnt)
  • Chemical Name: Siponimod (si-PON-i-mod)
  • Usage in MS: Disease-Modifying Agent
  • Generic Available: No

This is an oral medication in tablet form.


Mayzent® is an immune system-modulating therapy thought to act by retaining certain white blood cells in the body's lymph nodes, keeping them out of circulation and out of the central nervous system.  Mayzent® also enters the central nervous system (brain and spinal cord) where it may have direct anti-inflammatory and/or other effects.

Mayzent® is approved by the FDA for relapsing forms of multiple sclerosis, which include clinically isolated syndrome, relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS with relapses).

Click here to read the prescribing information for healthcare providers.

Click here to read the medication guide for patients.


The Mayzent® Patient Support Program

Financial Assistance Program

Alongside Mayzent™

What You Need to Know About Mayzent®

This video was created in Summer 2019 and features Amit Bar-Or, MD and Julie Fiol, MSCN. Information is accurate as of then. To learn more about Mayzent® and other disease modifying therapy options, download the Consensus on Disease Modifying Therapies.


© 2024 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.